Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics S.A.    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The tendency within the weekly time frame is positive above the technical support level at 3.48 EUR
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The stock is close to a major daily resistance at EUR 8.38, which should be gotten rid of so as to gain new appreciation potential.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
GENSIGHT BIOLOGICS S.A.194.57%349
GILEAD SCIENCES, INC.-5.94%76 052
VERTEX PHARMACEUTICALS5.18%59 224
REGENERON PHARMACEUTICALS36.91%54 464
WUXI APPTEC CO., LTD.57.04%38 135
BIONTECH SE236.51%29 915
GENMAB A/S61.59%25 135
BEIGENE, LTD.48.70%23 307
ARGENX SE66.85%13 534
MYOKARDIA, INC.208.58%11 993
-
MIRATI THERAPEUTICS, INC.81.87%11 959
HUALAN BIOLOGICAL ENGINEERI..59.18%11 938
SAREPTA THERAPEUTICS, INC.13.10%11 116
ASCENDIS PHARMA A/S21.20%9 013
NEUROCRINE BIOSCIENCES, INC..-11.68%8 870
ULTRAGENYX PHARMACEUTICAL I..174.83%7 842
More Results
Financials
Sales 2020 12,5 M 15,0 M 15,0 M
Net income 2020 -16,7 M -20,1 M -20,1 M
Net cash 2020 16,7 M 20,2 M 20,2 M
P/E ratio 2020 -12,3x
Yield 2020 -
Capitalization 290 M 349 M 350 M
EV / Sales 2020 21,9x
EV / Sales 2021 18,9x
Nbr of Employees 25
Free-Float 95,4%
Upcoming event on GENSIGHT BIOLOGICS S.A.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability -
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes